Lobbying disclosures · Lobbying report
VRTX: third_quarter 2026 lobbying report
Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
Follow VRTX- Became public
- Oct 20, 2026, 12:13 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 3:17 PM EST
Why this is connected
Legal-name match: VERTEX PHARMACEUTICALS INCORPORATED is VERTEX PHARMACEUTICALS INC / MA (https://www.sec.gov/Archives/edgar/data/875320/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $50,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/ca92a560-141e-4a26-98b1-69bc360b91a6/","filing_uuid":"ca92a560-141e-4a26-98b1-69bc360b91a6","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/ca92a560-141e-4a26-98b1-69bc360b91a6/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"James \"J.D.\" Derderian","dt_posted":"2026-10-20T12:13:30-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"182 Prince George Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Annapolis","registrant_state":"MD","registrant_zip":"21401","registrant":{"id":83717,"url":"https://lda.gov/api/v1/registrants/83717/","house_registrant_id":36456,"name":"STANTON PARK GROUP","description":"government affairs","address_1":"182 Prince George Street","address_2":null,"address_3":null,"address_4":null,"city":"Annapolis","state":"MD","state_display":"Maryland","zip":"21401","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAMES DERDERIAN","contact_telephone":"+1 202-549-1472","dt_updated":"2026-07-28T16:47:17.343412-04:00"},"client":{"id":172103,"url":"https://lda.gov/api/v1/clients/172103/","client_id":1000560,"name":"VERTEX PHARMACEUTICALS INCORPORATED","general_description":"Global biotechnology company","client_government_entity":false,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2010-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139835,"prefix":"mr","prefix_display":"MR.","first_name":"BRYAN","nickname":null,"middle_name":"WILLIAM","last_name":"WELLS","suffix":null,"suffix_display":null},"covered_position":"Policy Advisor, Senator Pat Roberts","new":false},{"lobbyist":{"id":54701,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"DERDERIAN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, House Commerce Committee; Legislative Advisor to Rep. Tom Bliley","new":false},{"lobbyist":{"id":53472,"prefix":null,"prefix_display":null,"first_name":"VALERIE","nickname":null,"middle_name":null,"last_name":"HENRY","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, Rep. Greg Walden; Legislative Assistant to Sen. John Warner and Sen. Mike Crapo","new":false},{"lobbyist":{"id":67522,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"RACHINSKY","suffix":"jr","suffix_display":"JR"},"covered_position":null,"new":false},{"lobbyist":{"id":148900,"prefix":null,"prefix_display":null,"first_name":"AISLING","nickname":null,"middle_name":null,"last_name":"MCDONOUGH","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Anna Eshoo; Senior Health Advisor, Rep. Anna Eshoo; Policy Coordinator, Energy & Commerce Committee; Legislative Assistant, Sen. Brian Schatz","new":false},{"lobbyist":{"id":153662,"prefix":null,"prefix_display":null,"first_name":"KEVIN","nickname":null,"middle_name":null,"last_name":"DAWSON","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Congressman Mike Kelly; Health Policy Advisor, Senator Bill Cassidy; Professional Staff Member, Senate Committee on the Budget","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in VRTX
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 5, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
Sold Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Aug 26, 2026 · disclosed Sep 5, 2026
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Bought Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
- Feb 2, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
Sold Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 2, 2026
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Bought Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Oct 23, 2024 · disclosed Jan 13, 2026 · filed 447 days later
- Sep 12, 2025$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Vertex Pharmaceuticals VRTX
$1K–$15K · Traded Aug 26, 2025 · disclosed Sep 12, 2025 · Dependent
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.